These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 32457020)

  • 21. Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials.
    Verdoia M; Khedi E; Ceccon C; Suryapranata H; De Luca G
    Int J Cardiol; 2018 Aug; 264():30-38. PubMed ID: 29776573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
    Gelbenegger G; Schoergenhofer C; Jilma B; Gager GM; Dizdarevic AM; Mamas MA; Parapid B; Velagapudi P; Siller-Matula JM
    Clin Pharmacol Ther; 2021 Aug; 110(2):424-431. PubMed ID: 33668076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P2Y
    Jin Y; Huang H; Shu X; Chen S; Lu L; Gao X; Wu Z
    Thromb Res; 2021 Feb; 198():115-121. PubMed ID: 33316640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y
    Lahu S; Bristot P; Gewalt S; Goedel A; Giacoppo D; Schüpke S; Schunkert H; Kastrati A; Sarafoff N
    J Atheroscler Thromb; 2022 Jul; 29(7):1001-1019. PubMed ID: 34248087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of very short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy in older patients undergoing percutaneous coronary intervention: meta-analysis of randomised controlled trials.
    Roule V; Lemaitre A; Pommier W; Bignon M; Sabatier R; Blanchart K; Beygui F
    Age Ageing; 2021 Jun; 50(4):1102-1107. PubMed ID: 33755049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Efficacy and Safety of Duration of Dual Antiplatelet Therapy in Patients with CAD Undergoing Drug-eluting Stent Implantation: A Systematic Review and Network Meta-analysis.
    Guan J; Song W; He P; Fan S; Zhi H; Wang L
    Curr Pharm Des; 2020; 26(44):5739-5745. PubMed ID: 32586248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P2Y
    Andò G; De Santis GA; Greco A; Pistelli L; Francaviglia B; Capodanno D; De Caterina R; Capranzano P
    JACC Cardiovasc Interv; 2022 Nov; 15(22):2239-2249. PubMed ID: 36423966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.
    Yin SH; Xu P; Wang B; Lu Y; Wu QY; Zhou ML; Wu JR; Cai JJ; Sun X; Yuan H
    BMJ; 2019 Jun; 365():l2222. PubMed ID: 31253632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P2Y12 Inhibitor Monotherapy After Short-Term Dual Antiplatelet Therapy in Acute Coronary Syndrome.
    Singh S; Garg A; Tantry US; Bliden K; Abbott JD; Gurbel PA
    Am J Cardiol; 2024 Aug; 224():1-8. PubMed ID: 38734399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
    Kuno T; Ueyama H; Takagi H; Bangalore S
    Am Heart J; 2020 Sep; 227():82-90. PubMed ID: 32693196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term vs long-term dual antiplatelet therapy after drug-eluting stent implantation in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Int J Clin Pract; 2021 Jul; 75(7):e13938. PubMed ID: 33341109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis.
    Luo L; Wang S; Tang K; Yang X; Wu J; Wang D; Xu L; Feng T; Li D; Ran J; Li D; Zhang L; Zhao D
    Medicine (Baltimore); 2022 Oct; 101(42):e31158. PubMed ID: 36281144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Selvaraj V; Chatterjee S; Hirai T; Abbott JD; Bavishi C
    Catheter Cardiovasc Interv; 2022 Dec; 100(7):1151-1158. PubMed ID: 36326115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.
    Shin ES; Her AY; Kim B; Hahn JY; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    J Korean Med Sci; 2023 Nov; 38(45):e383. PubMed ID: 37987108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysis.
    Garg A; Rout A; Farhan S; Waxman S; Giustino G; Tayal R; Abbott JD; Huber K; Angiolillo DJ; Rao SV
    Am Heart J; 2022 Aug; 250():1-10. PubMed ID: 35436504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials.
    Benenati S; Galli M; De Marzo V; Pescetelli F; Toma M; Andreotti F; Della Bona R; Canepa M; Ameri P; Crea F; Porto I
    Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):86-93. PubMed ID: 31942965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial.
    Yamamoto K; Watanabe H; Morimoto T; Domei T; Ohya M; Ogita M; Takagi K; Suzuki H; Nikaido A; Ishii M; Fujii S; Natsuaki M; Yasuda S; Kaneko T; Tamura T; Tamura T; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    Circ Cardiovasc Interv; 2021 May; 14(5):e010384. PubMed ID: 34003662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention.
    McClure JD; Ramsay JC; Berry C
    J Am Heart Assoc; 2020 Aug; 9(16):e017109. PubMed ID: 32779497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.